Gapping down
In reaction to disappointing earnings/guidance: NKA -8.1%, FCN -4.1%, EVEP -3.7%, RYAAY -1.0%
Select metals/mining stocks trading lower: GFI -1.7%, GDX -1.6%, ABX -1.4%, AU -1.2%, NEM -0.7%
Other news: RSH -22.2% (RadioShack and hedge fund investors are considering plans to bankruptcy auction, according to reports), PSTI -11.3% (announces significant new finding from its Phase I/II muscle injury trial; stock had been trading higher all last week), NKA -8.1% (announces suspension of common unit distribution ), CMRX -4% (Brincidofovir will not be considered in further clinical trials in ebola virus disease), EVEP -3.7% (announces reduction of quarterly distribution to $0.50 per unit, prior was $0.77), HART -1.8% (disclosed that it recently determined that it will need additional development and testing within its ongoing preclinical large-animal model testing of the HART-Trachea)
Analyst comments: ANF -2.2% (downgraded to Sell from Hold at Evercore ISI), GOLD -1.4% (downgraded to Neutral from Buy at UBS), GES -1.1% (downgraded to Sell from Hold at Evercore ISI), DFT -1% (downgraded to Neutral at Macquarie), ARR -0.9% (downgraded to Underperform at Credit Suisse), CYS -0.7% (downgraded to Underperform at Credit Suisse)
In reaction to disappointing earnings/guidance: NKA -8.1%, FCN -4.1%, EVEP -3.7%, RYAAY -1.0%
Select metals/mining stocks trading lower: GFI -1.7%, GDX -1.6%, ABX -1.4%, AU -1.2%, NEM -0.7%
Other news: RSH -22.2% (RadioShack and hedge fund investors are considering plans to bankruptcy auction, according to reports), PSTI -11.3% (announces significant new finding from its Phase I/II muscle injury trial; stock had been trading higher all last week), NKA -8.1% (announces suspension of common unit distribution ), CMRX -4% (Brincidofovir will not be considered in further clinical trials in ebola virus disease), EVEP -3.7% (announces reduction of quarterly distribution to $0.50 per unit, prior was $0.77), HART -1.8% (disclosed that it recently determined that it will need additional development and testing within its ongoing preclinical large-animal model testing of the HART-Trachea)
Analyst comments: ANF -2.2% (downgraded to Sell from Hold at Evercore ISI), GOLD -1.4% (downgraded to Neutral from Buy at UBS), GES -1.1% (downgraded to Sell from Hold at Evercore ISI), DFT -1% (downgraded to Neutral at Macquarie), ARR -0.9% (downgraded to Underperform at Credit Suisse), CYS -0.7% (downgraded to Underperform at Credit Suisse)